Autolus Therapeutics (AUTL) Competitors $1.41 +0.10 (+7.63%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AUTL vs. ANIP, APGE, IMCR, KNSA, IRON, SPRY, EWTX, VERA, TVTX, and GPCRShould you be buying Autolus Therapeutics stock or one of its competitors? The main competitors of Autolus Therapeutics include ANI Pharmaceuticals (ANIP), Apogee Therapeutics (APGE), Immunocore (IMCR), Kiniksa Pharmaceuticals (KNSA), Disc Medicine (IRON), ARS Pharmaceuticals (SPRY), Edgewise Therapeutics (EWTX), Vera Therapeutics (VERA), Travere Therapeutics (TVTX), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical products" industry. Autolus Therapeutics vs. ANI Pharmaceuticals Apogee Therapeutics Immunocore Kiniksa Pharmaceuticals Disc Medicine ARS Pharmaceuticals Edgewise Therapeutics Vera Therapeutics Travere Therapeutics Structure Therapeutics Autolus Therapeutics (NASDAQ:AUTL) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation. Do analysts rate AUTL or ANIP? Autolus Therapeutics currently has a consensus price target of $9.32, suggesting a potential upside of 572.92%. ANI Pharmaceuticals has a consensus price target of $80.13, suggesting a potential upside of 13.41%. Given Autolus Therapeutics' higher possible upside, analysts plainly believe Autolus Therapeutics is more favorable than ANI Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Autolus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00ANI Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has more volatility & risk, AUTL or ANIP? Autolus Therapeutics has a beta of 2.06, meaning that its stock price is 106% more volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. Does the MarketBeat Community favor AUTL or ANIP? ANI Pharmaceuticals received 210 more outperform votes than Autolus Therapeutics when rated by MarketBeat users. However, 68.25% of users gave Autolus Therapeutics an outperform vote while only 64.14% of users gave ANI Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAutolus TherapeuticsOutperform Votes23068.25% Underperform Votes10731.75% ANI PharmaceuticalsOutperform Votes44064.14% Underperform Votes24635.86% Which has better valuation & earnings, AUTL or ANIP? ANI Pharmaceuticals has higher revenue and earnings than Autolus Therapeutics. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAutolus Therapeutics$10.12M36.42-$208.38M-$0.86-1.61ANI Pharmaceuticals$614.38M2.50$18.78M-$1.14-61.97 Is AUTL or ANIP more profitable? Autolus Therapeutics has a net margin of 0.00% compared to ANI Pharmaceuticals' net margin of -1.28%. ANI Pharmaceuticals' return on equity of 15.87% beat Autolus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Autolus TherapeuticsN/A -63.65% -36.54% ANI Pharmaceuticals -1.28%15.87%6.88% Do insiders and institutionals believe in AUTL or ANIP? 72.8% of Autolus Therapeutics shares are held by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by company insiders. Comparatively, 12.7% of ANI Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media prefer AUTL or ANIP? In the previous week, Autolus Therapeutics had 7 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 16 mentions for Autolus Therapeutics and 9 mentions for ANI Pharmaceuticals. Autolus Therapeutics' average media sentiment score of 1.06 beat ANI Pharmaceuticals' score of 0.93 indicating that Autolus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Autolus Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ANI Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAutolus Therapeutics beats ANI Pharmaceuticals on 10 of the 18 factors compared between the two stocks. Get Autolus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AUTL vs. The Competition Export to ExcelMetricAutolus TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$368.54M$2.98B$5.54B$7.74BDividend YieldN/A1.89%5.11%4.22%P/E Ratio-1.1430.3022.4118.43Price / Sales36.42495.68393.33103.32Price / CashN/A168.6838.1834.62Price / Book2.163.186.724.23Net Income-$208.38M-$72.35M$3.22B$248.23M7 Day Performance-8.28%3.00%2.83%2.95%1 Month Performance-16.57%-0.35%-0.36%2.11%1 Year Performance-62.36%-21.54%17.84%5.31% Autolus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AUTLAutolus Therapeutics2.6974 of 5 stars$1.41+7.6%$9.32+561.0%-61.7%$375.19M$10.12M-1.17330Upcoming EarningsPositive NewsGap DownANIPANI Pharmaceuticals4.3469 of 5 stars$68.00-1.7%$80.13+17.8%+7.3%$1.48B$614.38M-123.64600APGEApogee Therapeutics2.2181 of 5 stars$32.85-0.8%$92.17+180.6%-22.0%$1.48BN/A-13.5791Positive NewsGap DownIMCRImmunocore3.0457 of 5 stars$29.41+3.5%$63.73+116.7%-49.1%$1.47B$310.20M-30.96320Upcoming EarningsPositive NewsKNSAKiniksa Pharmaceuticals2.4823 of 5 stars$20.05-0.8%$37.17+85.4%+44.1%$1.46B$423.24M-143.20220Earnings ReportAnalyst ForecastNews CoverageIRONDisc Medicine2.3669 of 5 stars$42.06-0.3%$93.80+123.0%+77.5%$1.45BN/A-10.5730Upcoming EarningsNews CoveragePositive NewsSPRYARS Pharmaceuticals3.118 of 5 stars$14.32-3.8%$31.00+116.5%+60.6%$1.41B$89.15M-28.0890Upcoming EarningsNews CoveragePositive NewsHigh Trading VolumeEWTXEdgewise Therapeutics3.2347 of 5 stars$13.30-1.1%$40.13+201.7%-8.6%$1.39BN/A-8.8760Upcoming EarningsAnalyst ForecastShort Interest ↑Positive NewsVERAVera Therapeutics2.9478 of 5 stars$21.11-0.8%$64.67+206.3%-40.9%$1.35BN/A-8.0940Upcoming EarningsNews CoveragePositive NewsGap DownTVTXTravere Therapeutics2.8991 of 5 stars$15.11+1.3%$32.08+112.3%+276.3%$1.34B$233.18M-3.69460GPCRStructure Therapeutics2.3571 of 5 stars$23.10+6.2%$81.29+251.9%-31.5%$1.32BN/A-31.22136Upcoming EarningsNews CoveragePositive NewsHigh Trading Volume Related Companies and Tools Related Companies ANI Pharmaceuticals Competitors Apogee Therapeutics Competitors Immunocore Competitors Kiniksa Pharmaceuticals Competitors Disc Medicine Competitors ARS Pharmaceuticals Competitors Edgewise Therapeutics Competitors Vera Therapeutics Competitors Travere Therapeutics Competitors Structure Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AUTL) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Autolus Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Autolus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AUTL Stock Free AUTL Stock Alerts